Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1430 participants.

Also called NCT04797013

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,430 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04797013
Other papers using this trial's data
  • Efficacy and Safety of Intravenous Tenecteplase Versus Alteplase in Treating Acute Ischemic Stroke With Diabetes and Admission Hyperglycemia Journal of the American Heart Association, 2024-10-15 DOI, PubMed 39392168, PMC11935594 In the PMC Open Access subset under CC BY-NC-ND.
  • Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial Lancet (London, England), 2023-02-25 DOI, PubMed 36774935 PubMed links an erratum for this paper. Erratum: PMID 37003696

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04797013. Randomized; single masking; primary purpose treatment. Start 2021-06-12 (actual); primary completion 2022-05-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ
Acronym
TRACEⅡ
Condition
Acute Ischemic Stroke
Intervention (Drug)
rt-PA
Intervention (Drug)
rhTNK-tPA
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04797013
Content hash
450617e88e49544a6245f8ed3b1ba78be7dc0537d6c4fe6dc9d9d108a31f9fe9